title: Intravenous ondansetron for postsurgical opioid-induced nausea and vomiting. S3A-255 Study Group.
abstract: The use of opioids for postoperative analgesia may be limited by side effects such as nausea and vomiting. Because ondansetron, a selective serotonin type 3 (5-hydroxytryptamine [5-HT3]) antagonist, is effective for chemotherapy and general anesthesia-induced nausea and vomiting, we hypothesized that it may also be effective for opioid-induced nausea and vomiting. ASA physical status I-III patients undergoing regional anesthesia were eligible for the study. Those who requested an antiemetic after postsurgical opioid administration were randomized to receive a single dose of ondansetron (0.1 mg, 4 mg, or 16 mg intravenously [I.V.]) or placebo in a double-blind fashion. Emetic episodes, nausea and pain ratings, and adverse events were recorded for 24 h after study drug administration. Patient satisfaction scores were obtained 24 h after study drug infusion. A significantly (P < 0.05) larger proportion of patients treated with ondansetron 4 mg and 16 mg experienced no emetic episodes, received no rescue antiemetic, and completed the study compared with placebo. Nausea scores and patient satisfaction scores in the ondansetron 16-mg group were significantly (P < 0.05) more favorable than in the placebo group. Postsurgical pain scores did not differ among groups. The incidence of adverse events was similarly low across groups. The results of this study support our hypothesis that I.V. ondansetron is effective for postsurgical opioid-induced nausea and vomiting.
authors.affiliation: Milton S. Hershey Medical Center, Pennsylvania State University, 17033, USA.
authors.forename: G W
authors.initials: GW
authors.lastname: Rung
authors.forename: L
authors.initials: L
authors.lastname: Claybon
authors.forename: A
authors.initials: A
authors.lastname: Hord
authors.forename: C
authors.initials: C
authors.lastname: Patel
authors.forename: M
authors.initials: M
authors.lastname: Kallgren
authors.forename: J
authors.initials: J
authors.lastname: Koppel
authors.forename: C
authors.initials: C
authors.lastname: Benedetti
authors.forename: M
authors.initials: M
authors.lastname: Creed
authors.forename: A
authors.initials: A
authors.lastname: Asgharian
authors.forename: J
authors.initials: J
authors.lastname: Bryson
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000701:Analgesics, Opioid / Q000009:adverse effects*; D000932:Antiemetics / Q000008:administration & dosage*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000517:prevention & control*; D017294:Ondansetron / Q000008:administration & dosage*; D011183:Postoperative Complications / Q000517:prevention & control*; D014839:Vomiting / Q000517:prevention & control*
chemical_list: D000701:Analgesics, Opioid; D000932:Antiemetics; D017294:Ondansetron